Biotechnology

Adlai Nortye

Adlai Nortye released FY2025 Q3 earnings on April 10 (EST), actual revenue USD 2.5 M, actual EPS USD -0.2686

Adlai Nortye released FY2025 9 Months Earnings on April 10, 2026 (EST) with actual revenue of USD 2.5 M and EPS of USD -0.8424

Adlai Nortye released FY2025 Q4 earnings on April 10 (EST), actual revenue USD 2.5M, actual EPS USD -0.2686

Adlai Nortye released FY2025 earnings on April 10 (EST), actual revenue USD 5.396 M (forecast USD 8 M), actual EPS USD -1.1111

Adlai Nortye released FY2025 Semi-Annual Earnings on December 29 (EST), actual revenue USD 0, actual EPS USD -0.5737

Adlai Nortye released FY2025 Q2 earnings on December 29 (EST) with actual revenue of USD 0 and EPS of USD -0.2868

Adlai Nortye released FY2025 Q1 earnings on December 29 (EST), actual revenue USD 70K, actual EPS USD -0.2868

Adlai Nortye Ltd. reports half-year net loss of 18.3 million dollars, down 33.6% year-over-year

Adlai Nortye Ltd. signs exclusive licensing agreement with ASK Pharm

Adlai Nortye Ltd. renamed to Adlai Nortye Group Ltd. and relocated to Singapore

Adlai Nortye Ltd. to Present Clinical Data for Antibody-Drug Conjugate AN4035 at AACR-NCI-EORTC

Adlai Nortye Ltd to Present New Drug Candidate at International Conference

HC Wainwright downgrades Adlai Nortye to neutral

Adlai Nortye Ltd. Stock Price Rises but Volume Is Low

Adlai Nortye released FY2024 Annual Earnings on April 30, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.6246

Adlai Nortye released FY2024 Q4 earnings on April 30 EST, actual revenue USD 0, actual EPS USD -0.3215

Adlai Nortye released FY2024 9-month earnings on April 30 (EST), actual revenue USD 0, actual EPS USD -1.3782

Adlai Nortye released FY2024 Q3 earnings on April 30, 2025, EST: Actual Revenue USD 0, Actual EPS USD -0.3215

Adlai Nortye Announces First Patient Treated with PALUPIPRANT for Locally Advanced Rectal Cancer

Adlai Nortye released FY2023 Q4 earnings on April 19 (EST) with actual revenue of USD 0 and EPS of USD -0.7546

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

Capstone

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

MetaVia

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Adlai Nortye's President and Head of R&D, Archie Tse, has filed an initial beneficial ownership statement, reporting ownership of 50,000 American Depository Shares as of March 18, 2026.

PUBT

Adlai Nortye President, Head of R&D Archie Tse files initial beneficial ownership statement

CDNA

In Thursday's pre-market session, several health care stocks saw significant movements. Gainers included Adlai Nortye (ANL) up 16.9% to $15.5, Aligos Therapeutics (ALGS) up 15.22% to $8.55, and CareDx (CDNA) up 10.13% to $19.35. Conversely, QuidelOrtho (QDEL) fell 16.2% to $14.65, Inotiv (NOTV) dropped 15.3% to $0.33, and Wellgistics Health (WGRX) declined 14.98% to $0.13. The Q4 earnings report was released yesterday.

benzinga_article

Caredex

SPDR S&P Biotech

iShares Global Healthcare

iShares US Pharma

iShares Biotechnology ETF

SPDR Pharmac

VG Health

Health Care Select Sector SPDR

Aligos Therapeutics

Hims & Hers Health

Vivani Medical

American Shared Hosp

QuidelOrtho

Inotiv

Wellgistics Health

NewGenIvf

MeiraGTx

Vivos Therapeutics

NEWGENIVF GROUP LIMITED C/WTS 03/04/2029(TO PUR COM)

12 Health Care Stocks Moving In Thursday's Pre-Market Session

SBIO

IBBQ

ARKG

Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing.

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Adlai Nortye rose 3.55% in after-hours trading; Immutep rose 15.92% in after-hours trading, with a transaction volume of USD 2.77 million; Moderna rose 0.17% in after-hours trading, with a transaction volume of USD 392,700; Medicus Pharma rose 29.59% in after-hours trading, with a transaction volume of USD 386,700

Price Alert

U.S. stock night market fluctuations: Adlai Nortye rose 3.55% in the night market, analysts' hold ratings fail to boost market confidence, funds flow to other stocks

Adlai Nortye (NASDAQ:ANL) saw its stock price drop by 11.7% to $13.84, with trading volume increasing by 62% to 967,940 shares. Analysts have mixed opinions: Weiss Ratings maintains a 'sell' rating, while HC Wainwright upgraded it to 'buy' with a $16 target. Leerink Partners rated it 'outperform' with a $23 target. Currently, the consensus rating is 'Hold' with an average price target of $19.50. Adlai Nortye specializes in fine chemicals, particularly amino acids and derivatives, serving various markets including animal feed and pharmaceuticals.

Market Beat

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Adlai Nortye (NASDAQ:ANL) Trading Down 11.7%  - Here's What Happened

Adlai Nortye (NASDAQ:ANL) reached a new 52-week high of $14.30, closing at $13.8150 with a trading volume of 195,199 shares. Analysts have mixed opinions: Weiss Ratings maintains a 'sell' rating, while Leerink Partners set an 'outperform' rating with a $23 target. HC Wainwright upgraded it to 'buy' with a $16 target. The stock has a consensus rating of 'hold' and an average target price of $19.50. Adlai Nortye specializes in fine chemicals, particularly amino acids, serving various markets including animal feed and pharmaceuticals.

Adlai Nortye (NASDAQ:ANL) Reaches New 52-Week High  - Should You Buy?

Adlai Nortye Ltd. (NASDAQ:ANL) experienced a significant increase in short interest in March, rising 27.1% to 1,065,214 shares. The short-interest ratio is currently 5.5 days, with 2.9% of shares sold short. Analysts have mixed ratings, with Weiss Ratings maintaining a 'sell' and HC Wainwright upgrading to 'buy' with a $16 target. The stock opened at $6.46, with a one-year range of $0.88 to $12.09. Adlai Nortye specializes in fine chemicals, particularly amino acids and derivatives, serving various markets including animal feed and pharmaceuticals.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update

Wall Street Zen has upgraded Adlai Nortye (NASDAQ:ANL) to a "hold" rating. Other analysts have mixed views, with HC Wainwright raising it to "buy" with a $16.00 price target, while Weiss Ratings maintained a "sell" rating. Currently, Adlai Nortye's stock is down 3.6%, trading at $8.91, with a consensus price target of $16.00. The company specializes in fine chemicals, particularly amino acids, and has a twelve-month price range of $0.88 to $12.09.

Wall Street Zen Upgrades Adlai Nortye (NASDAQ:ANL) to Hold

Adlai Nortye(ANL.US)